At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave ...

Q1 2025 Earnings Call Transcript May 8, 2025 Crinetics Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

"Oczyesa has the potential to advance the standard of care for patients living with acromegaly by enhancing ... of mean IGF-1 values and reduction of symptoms were confirmed over 52 weeks in ...

Acromegaly was still suspected ... removal of the pituitary microadenoma resulted in significant improvement in symptoms. The case report underscored “the value of considering genetic and ...

Furthermore, the study showed improvements in symptoms, quality of life ... of three chronic and severe disease indications: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET ...

The studies highlighted that Oczyesa® led to a higher proportion of patients achieving normalized insulin growth-factor-1 (IGF-1) levels, which is crucial for managing acromegaly. It also showed ...

Furthermore, the study showed improvements in symptoms, quality of life ... on quality of life and mortality of patients with acromegaly.5,6 The prevalence of acromegaly is estimated to about ...

leading to weight gain and other symptoms and can shorten life expectancy. Meanwhile, Signifor LAR is a monthly depot formulation used to treat acromegaly, overgrowth of bone caused by a pituitary ...

Diets high in sugar, unhealthy fats, and processed foods can also contribute to insulin resistance, while certain hormonal disorders, like acromegaly ... not experience any symptoms, especially ...